BiotechTube

QR-504a

Phase 1Withdrawn
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fuchs Endothelial Corneal Dystrophy

Conditions

Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases, LRS, Descemet's Membrane Disorder

Trial Timeline

Aug 10, 2021 → Apr 12, 2022

NCT ID
NCT05052554

About QR-504a

QR-504a is a phase 1 stage product being developed by ProQR for Fuchs Endothelial Corneal Dystrophy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05052554. Target conditions include Fuchs Endothelial Corneal Dystrophy, FECD3, Corneal Diseases.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05052554Phase 1Withdrawn

Competing Products

1 competing product in Fuchs Endothelial Corneal Dystrophy

See all competitors
ProductCompanyStageHype Score
DT-168Design TherapeuticsPhase 2
47

Other Products from ProQR

sepofarsenPhase 2/3
57
sepofarsenPhase 2/3
57
QR-1123Phase 1/2
33
QR-421aPhase 1/2
33
QR-010 + PlaceboPhase 1/2
33